




## Biotech-Pharma (Therapy)

# Melatonin analogous for the colon cancer treatment

TECHNOLOGY  
TRANSFER OFFICE  
Andalusian Public Health System

A research group from the Andalusian Public Health System (SSPA) has demonstrated that a melatonin analogous can be used for the colon cancer treatment.



### Description

Colorectal cancer is a neoplasia whose incidence rate has been growing in the last few years and will become one of the most relevant malignant tumours in a near future.

The melatonin analogue capacity of inhibiting the growth and development of tumours is already well known. It affects cell proliferation in a variety of tumour cell lines, both in physiological and pharmacological concentrations.

Nevertheless, it is not known yet whether this melatonin analogue would be such effective against colon cancer as melatonin is.

In this context, a research group from the Andalusian Public Health System has demonstrated that a melatonin analogue inhibits the growth of cell lines of colon cancer *in vitro* and *in vivo*, suggesting the oncostatic / cytotoxic role of this compound.



### Advantages

1. It inhibits the growth of the colon cancer cell lines both *in vitro* and *in vivo*.
2. This melatonin analogue is a safe compound to be administered to humans.



### Intellectual Property

This technology is protected by patent.



### Aims

The research group is looking for a license and/or a collaboration agreement to further develop and exploit the technology.



### Classification

Area: Biotech-Pharma (Therapy)

Technology: Drug Administration

Pathology: Oncology and Hematology / Digestive System